YourBio Health enables individuals to collect a blood sample from home and receive test results via a secure website, providing access to and control of personal health data. The service is led by Harry Wilcox. The company was founded by Flagship Pioneering and is based in Boston, MA. YourBio intends to use new capital to accelerate growth and support forthcoming product launches. Financially, the company raised $21M in funding in a round led by Flagship Pioneering with participation from Newpath Partners. The article highlights Flagship Pioneering's background: since its launch in 2000, through Flagship Labs it has originated more than 100 scientific ventures and generated over $130 billion in aggregate value. Seventh Sense Biosystems, based in Medford, MA, has designed TAP™, a first push-button blood collection device positioned on a patient’s upper arm. TAP is currently under FDA 510(k) review and is not yet for sale. Future versions are planned to enable patients to collect their own blood anywhere and anytime. The company is led by CEO Howard Weisman with Stuart Blitz serving as Chief Business Officer. Seventh Sense says it will use the new funding to develop new products and expand production capacity. Seventh Sense Biosystems develops and commercializes the Touch Activated Phlebotomy (TAP) platform, a virtually painless micro-needle and microfluidic system that collects capillary blood without venipuncture. The company is focused on enabling point-of-care diagnostic testing in hospitals, doctor’s offices and clinical trials by reducing discomfort and logistical barriers to blood sampling. When fully commercialized, TAP is expected to incorporate additional capabilities for sample separation, dried blood spot collection and on-board diagnostic abilities. 7SBio’s TAP device is designed for fully automated, high-throughput manufacturing and includes features such as anticoagulant stabilization and a visual collection indicator. The company has received notices of allowance for three U.S. patents and its first patent in October 2013. Founded in 2008 within Flagship VentureLabs and based in Cambridge, Mass., 7SBio plans to use recent financing to complete product development and move toward commercialization. Seventh Sense Biosystems is developing an array of products based on its proprietary Touch Activated Phlebotomy (TAP) painless blood collection platform, with an initial focus on point-of-care diagnostics. The company's lead product is a TAP-based, pain-free blood sampling device designed to interface with a broad range of analytical systems and reduce the discomfort, anxiety and hassle of blood collection. Seventh Sense plans to initiate the pivotal trial of its lead point-of-care device in early 2013 and to seek U.S. regulatory clearance in mid-2013. The company will use the closed Series A financing to complete clinical testing and to commercialize its first TAP-based blood collection device. It is concurrently developing a high-volume TAP blood collection system for a broad range of tests, supported by a $3.28 million grant from the Bill & Melinda Gates Foundation for low-resource settings. The Board has appointed Howard Weisman as President and CEO; he will also serve on the company's Board of Directors and brings extensive product launch and commercialization experience. Seventh Sense was founded in 2008 and is based in Cambridge, Mass. Seventh Sense Biosystems is developing the Touch Activated Phlebotomy™ (TAP) platform, a single-step, painless microfluidic blood collection system intended for broad diagnostic applications. TAP penetrates only the uppermost skin layers and transfers blood to a collection reservoir for analysis, and the system won an Edison Gold Medal for diagnostic innovation. The company plans to expand TAP to collect higher-volume samples and to develop disposable, fully integrated sample-and-test systems as well as devices that interface with handheld or benchtop instruments. Seventh Sense intends to optimize design, develop manufacturing methods, and integrate components into a simple, power-free device that nontechnical users can operate. The company says the platform is targeted at enabling point-of-care diagnostics in resource-poor settings and hard-to-sample populations. Seventh Sense emphasizes safety, scalability, and ease-of-use as core product attributes.

Total raised

$65M

Funding rounds

6

Latest round

Equity

Latest activity

Sep 2021